<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453294</url>
  </required_header>
  <id_info>
    <org_study_id>Bio-THRIVE</org_study_id>
    <nct_id>NCT03453294</nct_id>
  </id_info>
  <brief_title>Effect of THRIVE During Apneic Oxygenation in General Anesthesia on Biomarkers</brief_title>
  <acronym>Bio-THRIVE</acronym>
  <official_title>Effect of Trans Nasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) During Apneic Oxygenation in General Anesthesia on Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxygenation with high-flow nasal cannula with 100% oxygen have now been evaluated in a number
      of studies and the data are convincing. The THRIVE technique is able to oxygenate patients
      safely and vital parameters has been shown to be stable. But it is of great importance to
      evaluate this new concept regarding other potential negative physiological aspects such as
      biological stress response detected by blood-bourne biomarkers before implementing it into
      clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 22, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Biomarkers of oxidative stress such as Thiobarbituric acid reactive substances, Advanced Oxidation Protein Products,Reactive oxygen species and total antioxidant capacity in blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of neuronal injury</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Biomarkers of neuronal injury and stress in blood such as S100 and Nuclear Serum Enolase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of cardiac damage</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Biomarkers of cardiac damage in blood such as troponin and ProBNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of kidney injury</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Biomarkers of kidney injury in blood such as creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of RNA damage</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Markers of RNA damage in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory response</measure>
    <time_frame>Up to 2 hours after start of intervention</time_frame>
    <description>Biomarkers of Inflammatory response in blood such as cytokines and interleukins</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anesthesia</condition>
  <condition>Oxygen Toxicity</condition>
  <arm_group>
    <arm_group_label>Apnoeic oxygenation using THRIVE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygenation by apnoea oxygenation using THRIVE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endotracheal intubation and mechanical ventilation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilation and oxygenation by an endotracheal tub and mechanical ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Apnoeic oxygenation using THRIVE</intervention_name>
    <description>Apnoeic oxygenation using THRIVE</description>
    <arm_group_label>Apnoeic oxygenation using THRIVE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endotracheal intubation and mechanical ventilation</intervention_name>
    <description>Endotracheal intubation and mechanical ventilation</description>
    <arm_group_label>Endotracheal intubation and mechanical ventilation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults, &gt;18 years old.

          2. Laryngeal-surgery where apnea is of benefit for the surgeon (eg. intraoral or
             laryngeal surgery).

          3. Capable of understanding the study information and sign the written consent.

        Exclusion Criteria:

          1. American Society of Anaesthesiologist severity score &gt;2

          2. New York Heart Association score &gt;2

          3. Pacemaker or ICD.

          4. Body Mass Index &gt;35

          5. Pregnancy

          6. Manifest cardiac failure or coronary disease

          7. Severe gastrointestinal reflux.

          8. Neuromuscular disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Malin Jonsson Fagerlund</investigator_full_name>
    <investigator_title>Senior Consultant, Associate Professor</investigator_title>
  </responsible_party>
  <keyword>THRIVE</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

